BIBvsIVV
ProShares Ultra Nasdaq Biotechnology against iShares Core S&P 500 ETF — the fee, the flows, the book, and a year head-to-head.
Head to head
| BIB | IVV | |
|---|---|---|
| Expense ratio | 0.95% | 0.030% |
| Assets | $93M | $882.6B |
| Net flow, 1 month | −$3M | −$4.7B |
| Net flow, 1 year | −$11M | +$69.9B |
| Return, YTD | +37.6% | +12.9% |
| Return, 1 year | +73.2% | +15.0% |
| Avg daily volume | 8K | 9.9M |
| Holdings | 229 | 507 |
| Listed | Apr 9, 2010 | May 15, 2000 |
| Options market | Yes | Yes |
MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS